Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T54229
(Former ID: TTDR00240)
|
|||||
Target Name |
Angiogenin (ANG)
|
|||||
Synonyms |
Ribonuclease 5; RNase 5; RNASE5
Click to Show/Hide
|
|||||
Gene Name |
ANG
|
|||||
Target Type |
Literature-reported target
|
[1] | ||||
Function |
Stimulates ribosomal RNA synthesis including that containing the initiation site sequences of 45S rRNA. Cleaves tRNA within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs) which inhibit protein synthesis and triggers the assembly of stress granules (SGs). Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo. Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus.
Click to Show/Hide
|
|||||
BioChemical Class |
Endoribonucleases
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.1.27.-
|
|||||
Sequence |
MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLT
SPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRA TAGFRNVVVACENGLPVHLDQSIFRRP Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Glutathione | Ligand Info | |||||
Structure Description | Human angiogenin PD/ALS variant R121C | PDB:5M9V | ||||
Method | X-ray diffraction | Resolution | 1.70 Å | Mutation | Yes | [3] |
PDB Sequence |
DNSRYTHFLT
11 QHYDAKPQGR21 DDRYCESIMR31 RRGLTSPCKD41 INTFIHGNKR51 SIKAICENKN 61 GNPHRENLRI71 SKSSFQVTTC81 KLHGGSPWPP91 CQYRATAGFR101 NVVVACENGL 111 PVHLDQSIFC121 R
|
|||||
|
||||||
Ligand Name: Pyrophosphate 2- | Ligand Info | |||||
Structure Description | Binding of Phosphate and Pyrophosphate ions at the active site of human Angiogenin as revealed by X-ray Crystallography | PDB:1H52 | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | Yes | [4] |
PDB Sequence |
DNSRYTHFLT
11 QHYDAKPQGR21 DDRYCESIMR31 RRGLTSPCKD41 INTFIHGNKR51 SIKAICENKN 61 GNPHRENLRI71 SKSSFQVTTC81 KLHGGSPWPP91 CQYRATAGFR101 NVVVACENGL 111 PVHLDQSIFR121 RP
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
Degree | 1 | Degree centrality | 1.07E-04 | Betweenness centrality | 0.00E+00 |
---|---|---|---|---|---|
Closeness centrality | 1.43E-04 | Radiality | 5.80E-03 | Clustering coefficient | 0.00E+00 |
Neighborhood connectivity | 2.00E+00 | Topological coefficient | 1.00E+00 | Eccentricity | 2 |
Download | Click to Download the Full PPI Network of This Target | ||||
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
NetPath Pathway | [+] 2 NetPath Pathways | + | ||||
1 | IL2 Signaling Pathway | |||||
2 | TGF_beta_Receptor Signaling Pathway | |||||
Reactome | [+] 1 Reactome Pathways | + | ||||
1 | Adherens junctions interactions |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 2 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 3 | Structural insights into human angiogenin variants implicated in Parkinson's disease and Amyotrophic Lateral Sclerosis. Sci Rep. 2017 Feb 8;7:41996. | |||||
REF 4 | Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography. Protein Sci. 2001 Aug;10(8):1669-76. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.